Olympiad Research LP Takes $160,000 Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Olympiad Research LP purchased a new stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) during the 4th quarter, Holdings Channel.com reports. The fund purchased 17,401 shares of the medical technology company’s stock, valued at approximately $160,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp lifted its holdings in shares of Alphatec by 10.1% during the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock valued at $17,453,000 after buying an additional 287,350 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after buying an additional 297,850 shares during the period. Royce & Associates LP lifted its holdings in shares of Alphatec by 15.9% during the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock valued at $6,740,000 after buying an additional 165,954 shares during the period. New York State Common Retirement Fund raised its holdings in Alphatec by 21.2% in the 4th quarter. New York State Common Retirement Fund now owns 1,202,334 shares of the medical technology company’s stock worth $11,037,000 after purchasing an additional 210,519 shares during the period. Finally, Walleye Capital LLC raised its holdings in Alphatec by 3.2% in the 3rd quarter. Walleye Capital LLC now owns 1,061,462 shares of the medical technology company’s stock worth $5,902,000 after purchasing an additional 32,529 shares during the period. 66.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

ATEC has been the topic of a number of recent research reports. Needham & Company LLC raised their target price on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Finally, Barclays raised their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Alphatec Price Performance

NASDAQ:ATEC opened at $10.61 on Monday. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The business’s 50-day simple moving average is $10.48 and its two-hundred day simple moving average is $8.26. The stock has a market cap of $1.50 billion, a PE ratio of -8.29 and a beta of 1.43. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $15.69.

Insider Buying and Selling at Alphatec

In other news, COO Scott Lish sold 27,453 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the completion of the transaction, the chief operating officer now owns 867,677 shares in the company, valued at $9,969,608.73. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Patrick Miles sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $12.03, for a total value of $601,500.00. Following the transaction, the chief executive officer now owns 6,152,544 shares of the company’s stock, valued at approximately $74,015,104.32. The trade was a 0.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 222,376 shares of company stock valued at $2,557,148 over the last ninety days. 22.80% of the stock is currently owned by company insiders.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.